Kymera Therapeutics (KYMR) Competitors $48.39 -0.21 (-0.43%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$48.39 0.00 (0.00%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. MRNA, ASND, VTRS, QGEN, BPMC, ROIV, RVMD, BBIO, ELAN, and VRNAShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Its Competitors Moderna Ascendis Pharma A/S Viatris Qiagen Blueprint Medicines Roivant Sciences Revolution Medicines BridgeBio Pharma Elanco Animal Health Verona Pharma Kymera Therapeutics (NASDAQ:KYMR) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability. Do analysts rate KYMR or MRNA? Kymera Therapeutics presently has a consensus target price of $59.82, suggesting a potential upside of 23.63%. Moderna has a consensus target price of $46.61, suggesting a potential upside of 67.97%. Given Moderna's higher probable upside, analysts clearly believe Moderna is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 3.00Moderna 4 Sell rating(s) 15 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Which has more volatility & risk, KYMR or MRNA? Kymera Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Does the media favor KYMR or MRNA? In the previous week, Moderna had 5 more articles in the media than Kymera Therapeutics. MarketBeat recorded 17 mentions for Moderna and 12 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.54 beat Moderna's score of 0.51 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, KYMR or MRNA? Kymera Therapeutics has higher earnings, but lower revenue than Moderna. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$58.89M53.51-$146.96M-$3.10-15.61Moderna$3.14B3.42-$3.56B-$8.73-3.18 Do insiders & institutionals have more ownership in KYMR or MRNA? 75.3% of Moderna shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 11.0% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is KYMR or MRNA more profitable? Moderna has a net margin of -110.04% compared to Kymera Therapeutics' net margin of -191.26%. Kymera Therapeutics' return on equity of -24.96% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-191.26% -24.96% -20.27% Moderna -110.04%-28.74%-21.83% Does the MarketBeat Community believe in KYMR or MRNA? Moderna received 151 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. However, 56.52% of users gave Kymera Therapeutics an outperform vote while only 53.07% of users gave Moderna an outperform vote. CompanyUnderperformOutperformKymera TherapeuticsOutperform Votes6556.52% Underperform Votes5043.48% ModernaOutperform Votes21653.07% Underperform Votes19146.93% SummaryKymera Therapeutics beats Moderna on 11 of the 18 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.15B$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-20.6833.3227.1320.06Price / Sales53.51469.84412.28157.10Price / CashN/A168.6838.2534.64Price / Book6.803.457.064.70Net Income-$146.96M-$72.35M$3.23B$247.88M7 Day Performance1.53%6.23%2.86%2.63%1 Month Performance50.42%16.53%9.05%6.36%1 Year Performance39.86%-16.90%31.39%14.05% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics2.3302 of 5 stars$48.39-0.4%$59.82+23.6%+40.0%$3.15B$58.89M-20.68170MRNAModerna4.5276 of 5 stars$28.14+2.5%$53.58+90.4%-81.3%$10.88B$3.14B-3.033,900Trending NewsASNDAscendis Pharma A/S3.5658 of 5 stars$173.15+0.1%$217.73+25.7%+30.2%$10.56B$368.70M-24.39640Analyst ForecastAnalyst RevisionVTRSViatris2.5528 of 5 stars$8.81+1.1%$10.40+18.0%-15.6%$10.34B$14.33B-11.9137,000QGENQiagen3.3487 of 5 stars$46.17+1.5%$48.42+4.9%+9.2%$10.26B$2.00B128.566,030BPMCBlueprint Medicines1.1972 of 5 stars$127.97+0.1%$129.35+1.1%+21.4%$8.26B$562.12M-118.49640High Trading VolumeROIVRoivant Sciences2.4436 of 5 stars$11.08-1.3%$17.50+57.9%+6.7%$7.91B$29.05M-73.86860RVMDRevolution Medicines4.4487 of 5 stars$40.58-1.2%$67.08+65.3%+4.5%$7.56B$742K-11.30250Positive NewsBBIOBridgeBio Pharma4.6239 of 5 stars$39.03+1.1%$57.36+47.0%+42.1%$7.41B$127.42M-13.69400Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionELANElanco Animal Health1.1137 of 5 stars$13.94+0.3%$15.17+8.8%-22.3%$6.92B$4.43B34.859,800Positive NewsVRNAVerona Pharma2.3658 of 5 stars$84.64+0.4%$82.13-3.0%+573.5%$6.86B$118.54M-44.0830Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies MRNA Competitors ASND Competitors VTRS Competitors QGEN Competitors BPMC Competitors ROIV Competitors RVMD Competitors BBIO Competitors ELAN Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KYMR Stock Free KYMR Stock Alerts